NEW YORK, Aug. 27 - OmniViz said it will release on Saturday new bioinformatics software co-developed by Johnson & Johnson's pharmaceutical R&D arm.
The software allows researchers to mine data from various sources, including text and patent searches, clinical information, and genomic and proteomic data, according to Jeff Saffer, chief technology officer and acting president of OmniViz.
The technology was designed through an ongoing relationship with J&J, through which the pharma company gets early access to software updates and input in software design, said Saffer.
Though he declined to disclose what J&J pays for the early access, Saffer described the collaboration as a "long-term relationship."
Michael Jackson, vice president for drug discovery at R W Johnson Pharmaceutical Research Institute, said his bioinformatics staff is working closely with OmniViz. The software, he said, "mixes different data sources together. I believe this is where you have to go."
Maynard, Mass.-based OmniViz has a similar relationship with BASF Plant Sciences, said Saffer.